nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-1327Research ArticleШКОЛА НЕФРОЛОГАEDUCATIONAL MATERIALSНизкомолекулярный декстран железа и сахарат железа обладают сравнимыми параметрами безопасности при хронических заболеваниях почекLow-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney diseaseАуэрбахМ. .AuerbachM. .mauerbachmd@aol.comТалибК. Ал.TalibK. Al.noemail@neicon.ruЦентр Гематологии и Онкологии Ауэрбаха, Балтимор, Мериленд, СШАRussian FederationМедицинский центр Франклина, отделение Нефрологии, Балтимор, Мериленд, СШАRussian Federation200819062025102159165Copyright © Ауэрбах М..., Талиб К.А., 20252025Ауэрбах М..., Талиб К.А.Auerbach M..., Talib K.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/1327

Тяжелые побочные реакции, встречавшиеся при применении декстрана железа, были обусловлены препаратами с высокой молекулярной массой. Суждения о том, что сахарат и глюконат железа более безопасны, чем декстран железа, преждевременны. Проанализированы опубликованные сравнения данных о безопасности доступных препаратов парентерального железа. Встречаются неоптимальные схемы применения препаратов железа у пациентов на додиализной стадии хронических заболеваний почек. Мы рекомендуем инфузию общей дозы низкомолекулярного декстрана железа как метод выбора для восполнения железа. Kidney International (2008) 73, 528-530.

Serious adverse events that occur with the administration of iron dextran are due to the high molecular weight preparations. Conclusions that iron sucrose and ferric gluconate are safer than iron dextran may be premature. Published literature comparing safety profiles of available parenteral iron products is reviewed. Administration of iron salts to pre-dialysis patients with chronic kidney disease may not be optimal. We recommend the total dose infusion of low molecular weight iron dextran as an option for iron replacement. Kidney International (2008) 73, 528-530.

ReferencesFeldman H.I., Joffe M., Robinson B. et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632.Feldman H.I., Joffe M., Robinson B. et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632.Kalanter-Zadeh K., Regidor D.L., McAllister C.J. et al. Time dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.Kalanter-Zadeh K., Regidor D.L., McAllister C.J. et al. Time dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.Blaustein D.A., Schwenk M.H., Chattopadhyay J., Avram M.M. Recent experience with high-dose intravenous iron administration. Kidney Int 2006; 70: S26-S29.Blaustein D.A., Schwenk M.H., Chattopadhyay J., Avram M.M. Recent experience with high-dose intravenous iron administration. Kidney Int 2006; 70: S26-S29.Vikrant S. Optimum dosage regimen for iron sucrose. Kidney Int 2007; 72: 225.Vikrant S. Optimum dosage regimen for iron sucrose. Kidney Int 2007; 72: 225.Chandler G., Harchowal J., Macdougall I.C. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991.Chandler G., Harchowal J., Macdougall I.C. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988-991.Auerbach M., Witt D., Toler W. et al. Clinical use of the total dose infusion of iron dextran. J Lab Clin Med 1988; 111: 566-570.Auerbach M., Witt D., Toler W. et al. Clinical use of the total dose infusion of iron dextran. J Lab Clin Med 1988; 111: 566-570.Auerbach M., Ballard H., Glaspy J. Clinical update: intravenous iron for anemia. Lancet 2007; 369: 1502-1504.Auerbach M., Ballard H., Glaspy J. Clinical update: intravenous iron for anemia. Lancet 2007; 369: 1502-1504.Case G. Maintaining iron balance with total-dose infusion of iron dextran. ANNA J 1998; 25: 65-68.Case G. Maintaining iron balance with total-dose infusion of iron dextran. ANNA J 1998; 25: 65-68.Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant; 21: 378-382.Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant; 21: 378-382.Silverstein S.B., Rodger G.M. Parenteral iron therapy options. Am J Hematol; 76: 74-78.Silverstein S.B., Rodger G.M. Parenteral iron therapy options. Am J Hematol; 76: 74-78.Mamula P., Piccoli D.A., Peck S.N. et al. dose intravenous infusion of iron dextran for irondeficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr; 34: 286-290.Mamula P., Piccoli D.A., Peck S.N. et al. dose intravenous infusion of iron dextran for irondeficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr; 34: 286-290.Coyne D.W., Adkinson F.N. Jr., Nissenson A.R. et al. ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextransensitive and dextran-tolerant patients. Kidney Int; 63: 217-224.Coyne D.W., Adkinson F.N. Jr., Nissenson A.R. et al. ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextransensitive and dextran-tolerant patients. Kidney Int; 63: 217-224.McCarthy J.T., Regnier C.E., Leobertmann C.L., Bergstralh E.J. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran: a comparison of two products. Am J Nephrol; 20: 455-462.McCarthy J.T., Regnier C.E., Leobertmann C.L., Bergstralh E.J. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran: a comparison of two products. Am J Nephrol; 20: 455-462.Fletes R., Lazarus J.M., Gage J., Chertow J.M. Suspected iron dextran related adverse events in hemodialysis patients. Am J Kidney Dis; 37: 743-749.Fletes R., Lazarus J.M., Gage J., Chertow J.M. Suspected iron dextran related adverse events in hemodialysis patients. Am J Kidney Dis; 37: 743-749.Auerbach M., Rodgers G.M. Intravenous iron. N Engl J Med; 357: 93-94.Auerbach M., Rodgers G.M. Intravenous iron. N Engl J Med; 357: 93-94.Auerbach M., Winchester J., Wahab A. et al. randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis; 31: 81-86.Auerbach M., Winchester J., Wahab A. et al. randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis; 31: 81-86.Auerbach M., Ballard H., Trout J.R. et al. iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label randomized trial. J Clin Oncol; 22: 1301-1307.Auerbach M., Ballard H., Trout J.R. et al. iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label randomized trial. J Clin Oncol; 22: 1301-1307.Auerbach M., Chaudhry M., Goldman H., Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med; 131: 257-260.Auerbach M., Chaudhry M., Goldman H., Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med; 131: 257-260.Moniem K.A., Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: a comparison of preparations. Transfusion Altern Transfusion Med 2007; 9: 37-42.Moniem K.A., Bhandari S. Tolerability and efficacy of parenteral iron therapy in haemodialysis patients: a comparison of preparations. Transfusion Altern Transfusion Med 2007; 9: 37-42.Critchley J., Dundar Y. Adverse events associated with intravenous iron infusion (low-molecularweight iron dextran and iron sucrose): a systematic review. Transfusion Altern Transfusion Med 2007; 9: 8-36.Critchley J., Dundar Y. Adverse events associated with intravenous iron infusion (low-molecularweight iron dextran and iron sucrose): a systematic review. Transfusion Altern Transfusion Med 2007; 9: 8-36.Sav T., Tokgoz B., Sipahioglu M.H. Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29: 423-426.Sav T., Tokgoz B., Sipahioglu M.H. Is there a difference between allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail 2007; 29: 423-426.Zager R.A., Johnson A.C., Hanson S.Y., Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103.Zager R.A., Johnson A.C., Hanson S.Y., Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103.Pai A.B., Boyd A.V., McQuade C.R. et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007; 27: 343-350.Pai A.B., Boyd A.V., McQuade C.R. et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007; 27: 343-350.Agarwal R., Vasavada N., Sachs N.G., Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289.Agarwal R., Vasavada N., Sachs N.G., Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289.Zager R.A., Johnson A.C., Hanson S.W. Parenteral iron exacerbates experimental sepsis. Kidney Int 2004; 65: 2108-2112.Zager R.A., Johnson A.C., Hanson S.W. Parenteral iron exacerbates experimental sepsis. Kidney Int 2004; 65: 2108-2112.Zager R.A., Johnson A.C., Hanson S.W., Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF alpha release. Am J Physiol Renal Physiol 2005; 288: F295-F297.Zager R.A., Johnson A.C., Hanson S.W., Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF alpha release. Am J Physiol Renal Physiol 2005; 288: F295-F297.Agarwal R., Rizkala A.R., Kaskas M.O. et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int; 72: 638-642.Agarwal R., Rizkala A.R., Kaskas M.O. et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int; 72: 638-642.

The authors declare that there are no conflicts of interest present.